CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

The European Union's drug regulator has recommended approval of Moderna's updated formulation of COVID-19 shot Spikevax, the ...

Moderna has received marketing authorisation from the European Commission for its updated COVID-19 vaccine, Spikevax, which ...

Moderna Inc. (NASDAQ: MRNA) has announced plans to reduce its global workforce by approximately 10% by the end of the year ...

Moderna said it would trim roughly 10 per cent of its global workforce and have fewer than 5,000 employees by the end of the ...

The company last reported total revenues of $108M in Q1, down 35.3% Y/Y due to lower net product sales, particularly its ...

The target is to reduce its workforce to less than 5,000 from a level of 5,800 at the end of 2024, said chief executive ...

In a memo, CEO Stéphane Bancel said the job cuts are needed to align the struggling vaccine maker’s cost structure with the ...

The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...

MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline ...